Lv21
150 积分 2024-09-05 加入
Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis
3小时前
已完结
Obinutuzumab for PLA2R-associated membranous nephropathy
27天前
已关闭
An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
1个月前
已完结
Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies
2个月前
已完结
Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
2个月前
已关闭
MAJESTY: A Phase 3, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy
2个月前
已关闭
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
3个月前
已完结
Obinutuzumab for PLA2R-associated membranous nephropathy
3个月前
已完结
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
3个月前
已完结
325 Obinutuzumab Use in Early Relapse of Membranous Nephropathy
3个月前
已关闭
皖公网安备34019202002308
